canyon landscape



This purpose of this study is to help determine if UCB0599 (an oral therapy targeting alpha synuclein) can slow the progression/worsening of Parkinson’s disease. Due to the way the study drug works in the brain, it is not expected to provide immediate relief to Parkinson’s disease symptoms, but it may be able to delay their start or reduce their intensity in the long term by protecting neurons.

Who can participate

Males and females between 40 – 70 years of age, with a diagnosis of Parkinson’s disease within the last 2 years. Patient must be Parkinson’s disease treatment naïve and not expected to start Parkinson’s disease medications in the next 6 months.


There are sixteen in clinic study visits over 18 months.

Principle Investigator

Open and enrolling subjects.
Phoenix, Arizona
Total Participants
Primary Sponsor
UCB Biopharma SRL